Epigral Plans Capacity Expansion to Reach Rs 5,000 Crore Revenue by FY31
Epigral, a specialty chemicals manufacturer based in Gujarat, aims to double its revenue to Rs 5,000 crore by 2030-31 through capacity expansions in CPVC Resin and Epichlorohydrin (ECH). The company expects Rs 2,900 crore revenue this fiscal year, up from Rs 2,500-2,530 crore in 2026. Capacity for CPVC Resin and ECH is being doubled at its Dahej units, with a Rs 650 crore capex funded entirely through internal accruals. These expansions will partially contribute this year and more significantly from next year.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 35/100.
Outlets measured: economictimes, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 27 Sept, 10:00 am. Other outlets followed.